Praise for the Second Edition

Free To Choose Medicine is full of disturbing data about the unintended consequences of our nation’s quest for safe drugs seemingly without regard to cost. Bart Madden explains how we have lost sight of the goals of encouraging innovation, speed to market, and quick access for suffering patients, and he lays out a realistic plan for getting back on track.

— Hon. Jim DeMint
U.S. Senator – South Carolina

A provocative proposal that offers a libertarian solution for reform of the nation’s dysfunctional drug regulation.

— Henry I. Miller, M.D.
Former Director
FDA’s Office of Biotechnology

Bart Madden shines a bright light on the all-too-invisible damage caused by the FDA’s self-protective, dysfunctional, and ultimately lethal drug approval process. He explains how the FDA bureaucracy protects itself while allowing millions of people to suffer and die who could be helped by faster access to the newest medicines. The FDA uses approval processes appropriate to an era of adding machines and not supercomputers. Madden offers a 21st century information-age solution in Free To Choose Medicine  that would give consumers control over health decisions, allow faster access to life-saving and life-enhancing drugs, and ultimately reduce the cost of new medicines. This concise book explains how to keep the FDA monopoly from stifling innovation and crippling the life sciences industry. Madden offers the right cure for the ailing FDA.

— Grace-Marie Turner
President
Galen Institute

As [President Barack Obama] promotes his plan to increase the role of government in our healthcare, this timely and topical book brings some very important new ideas to the debate. By allowing individuals to contract with drug developers so they can gain access to innovative drugs that have completed safety trials, Americans will have the opportunity to live longer and healthier lives. The cost of new drugs will decline and research and development into new treatments will increase. It is a must-read for all legislators and the general public.

— Sally C. Pipes
President
Pacific Research Institute